DALLAS and NEW YORK, Nov. 19, 2010 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (BULLETIN BOARD: ACCP) , a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that its Chairman, Steven Rouhandeh, will appear on WALLSTREETCAST, a national weekly television program airing on the FOX Business Network. The show will air tomorrow, Saturday, November 20th at 1:30 PM ET. The segment may also be viewed online at http://www.moneychannel.tv/.
About Money Channel:
The Money Channel Inc., headquartered in Coconut Creek, Florida, has operated as a media company since 2004. Its CEO, Stephen Crowley, is a former Price Waterhouse and Co. CPA-Manager, the former Money Editor of ABC's Good Morning America as well as the author of Money for Life, published by Simon & Schuster Inc. Mr. Crowley and his team have produced more than 9,000 national radio and television programs since 1982 in markets ranging from New York to San Diego and from Seattle to Miami. American Scene Radio is also co-branded with Investors Business Daily at http://www.investors.com/americanscene and with http://www.thestreet.com/ founded by Jim Cramer.
About Access:
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard(TM) (http://www.mugard.com/), for the management of patients with mucositis, ProLindac(TM), currently in Phase II clinical testing of patients with ovarian cancer, and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers.
The company also has other advanced drug delivery technologies including CobaCyte(TM)-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com/.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.
Contact: Company Contact: Investor Relations ---------------- --------------------------- Donald C. Weinberger/Diana Bittner Christine Berni (media) Director of Investor Relations Wolfe Axelrod Weinberger Assoc. LLC Access Pharmaceuticals, Inc. (212) 370-4500 (212) 786-6208
Access Pharmaceuticals, Inc.
CONTACT: Christine Berni, Director of Investor Relations of Access
Pharmaceuticals, Inc., +1-212-786-6208; or Investor Relations, Donald C.
Weinberger, or Media, Diana Bittner, both of Wolfe Axelrod Weinberger Assoc.
LLC, +1-212-370-4500, both for Access Pharmaceuticals, Inc.
Web Site: http://www.accesspharma.com/
